New hope for Tough-to-Treat lymphoma: major trial tests promising injection
NCT ID NCT07011056
Summary
This study is testing whether a new injectable drug called Purinostat mesylate works better than the existing oral drug selinexor for adults with a fast-growing type of lymphoma that has come back or hasn't responded to prior treatments. About 390 participants will be randomly assigned to receive either the new injection or the standard pill to compare which one helps people live longer and shrinks tumors more effectively. The goal is to find a better option for controlling this difficult cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital Sichuan University
RECRUITINGChengdu, Sichuan, 610200, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.